Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

NCT01880385 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Breast Cancer

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Cyclophosphamide
DRUG: epirubicin hydrochloride
DRUG: fluorouracil
DRUG: Docetaxel
BIOLOGICAL: Trastuzumab

Sponsor

Association Tunisienne de lutte Contre le Cancer

Collaborators

[object Object]
[object Object]